NCT03327558View on ClinicalTrials.gov

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

June 23, 2017

Study Completion Date

August 18, 2017

Conditions
Ulcerative Colitis
Interventions
DRUG

Apriso 0.375G ER CAP

ER capsule

DRUG

APRISO 375 mg extended-release capsules

375 mg extended-release capsules

Trial Locations (1)

22434

Valeant Site 01, San Diego

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT03327558 - Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects | Biotech Hunter | Biotech Hunter